CCO
0.003
50%
NAE
0.001
-50%
M2R
0.003
50%
AOK
0.002
-33.3%
TOU
0.003
50%
ARV
0.003
-25%
AVE
0.021
40%
MQR
0.006
-25%
BLU
0.004
33.3%
KM1
0.08
-23.8%
HIQ
0.008
33.3%
COI
0.1
-23.1%
HYD
0.004
33.3%
AHN
0.004
-20%
M2M
0.01
25%
KTA
0.004
-20%
TGH
0.02
25%
XGL
0.008
-20%
BNZ
2.63
24.1%
BTE
0.04
-18.4%
UM1
0.145
20.8%
NOR
0.031
-18.4%
LKO
0.615
20.6%
LIS
0.115
-17.9%
AZI
0.024
20%
AVD
0.1
-16.7%
SIX
0.084
20%
ENL
0.005
-16.7%
NH3
0.11
17%
FEL
0.005
-16.7%
AM5
0.007
16.7%
RBX
0.03
-16.7%
GLL
0.007
16.7%
VIT
0.022
-15.4%
LMG
0.014
16.7%
T3D
0.035
-14.6%
PL9
0.007
16.7%
BNL
0.006
-14.3%
SIS
0.007
16.7%
FIN
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

EZZ Life Science (ASX: EZZ): Targets US expansion followingFDA product approvals

Australian genomic life science company EZZ Life Science (ASX: EZZ) has won approval from the United States (US) Food and Drug Administration (FDA) for nine of its products in the food category, presenting a significant US expansion opportunity for EZZ. | ASX announcement: https://announcements.asx.com.au/asxpdf/20240625/pdf/064x2fh3lh72px.pdf